Keywords: GLP-1 receptor agonists, obesity, weight loss, non-diabetic patients, cardiovascular outcomes, cost-effectiveness Introduction Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern [7] [8]

By leveraging berberine's documented ability to influence cellular energy regulation and glucose metabolism, this botanical product is positioned as an accessible, scientifically backed holistic alternative to naturally manage blood sugar levels and support sustainable wellness without relying solely on synthetic pharmaceuticals In December 2025, Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of two Phase III clinical studies of Mazdutide, the world's first approved glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-1, DREAMS-2) have been published back-to-back in Nature as Accelerated Article Previews (AAP)

For commercial, Medicare Advantage, and Medicaid payers, reimbursement may be based on your contract
However, treatment with a low dosage of erastin was capable of drastically reducing GSH with replication stress induction
Q: Will BPC-157 show up on a drug test